Aspergillosis - Pipeline Review, H2 2016

Published: Nov, 2016 | Pages: 108 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Aspergillosis - Pipeline Review, H2 2016, provides an overview of the Aspergillosis (Infectious Disease) pipeline landscape.

Aspergillosis is an infection or allergic response due to the Aspergillus fungus. Symptoms include cough, fever, headaches, general ill feeling (malaise), weight loss and chest pain. The predisposing factors include weakened immune system, low white blood cell level, asthma and long-term corticosteroid therapy. Treatment includes oral corticosteroids, antifungal and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Aspergillosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Aspergillosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Aspergillosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Aspergillosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 4, 18, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 3 molecules, respectively.Aspergillosis.

Aspergillosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Aspergillosis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Aspergillosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Aspergillosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Aspergillosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Aspergillosis (Infectious Disease)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Aspergillosis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Aspergillosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Aspergillosis Overview 10
Therapeutics Development 11
Pipeline Products for Aspergillosis - Overview 11
Pipeline Products for Aspergillosis - Comparative Analysis 12
Aspergillosis - Therapeutics under Development by Companies 13
Aspergillosis - Therapeutics under Investigation by Universities/Institutes 15
Aspergillosis - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Aspergillosis - Products under Development by Companies 20
Aspergillosis - Products under Investigation by Universities/Institutes 21
Aspergillosis - Companies Involved in Therapeutics Development 22
Amplyx Pharmaceuticals, Inc. 22
Astellas Pharma Inc. 23
Biomar Microbial Technologies 24
Biosergen AS 25
Cidara Therapeutics, Inc. 26
F2G Ltd 27
Hsiri Therapeutics LLC 28
iCo Therapeutics Inc. 29
Matinas BioPharma Holdings, Inc. 30
Merck & Co., Inc. 31
Nanomerics Ltd 32
Novabiotics Limited 33
Pulmatrix, Inc. 34
Pulmocide Ltd 35
Scynexis, Inc. 36
Sealife PHARMA GMBH 37
Sigma-Tau S.p.A. 38
TGV-Laboratories 39
Vical Incorporated 40
Aspergillosis - Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Target 42
Assessment by Mechanism of Action 44
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
amphotericin B - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
amphotericin B - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
amphotericin B - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
amphotericin B - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Amphotericin B sodium - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
APX-001 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
ASP-9726 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
Aspergillus fumigatus vaccine - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
BSG-005 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
C-001 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
C-016 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
celastrol - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
Cellullar Immunotherapy for Viral Infections and Fungal Infections - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
F-901318 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
itraconazole - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
KB-425796C - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
MDN-0018 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
Myc-102 - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
NP-339 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
NP-525 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
PC-945 - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
posaconazole - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
PTX-3 - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
SCY-078 - Drug Profile 81
Product Description 81
Mechanism Of Action 81
R&D Progress 81
SLP-0901 - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
SLP-0904 - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
Small Molecule for Aspergillosis - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
Small Molecules for Aspergillosis and Candidiasis - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
Small Molecules for Fungal Infections - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
Small Molecules for Fungal Infections - Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
Small Molecules for Invasive Aspergillosis - Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
Vaccine for Fungal Infections - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
VL-2397 - Drug Profile 93
Product Description 93
Mechanism Of Action 93
R&D Progress 93
Aspergillosis - Dormant Projects 94
Aspergillosis - Discontinued Products 95
Aspergillosis - Product Development Milestones 96
Featured News & Press Releases 96
Oct 26, 2016: F2G Announces Publication of Initial F901318 Data in Scientific Journal PNAS 96
Sep 12, 2016: Amplyx Pharmaceuticals Initiates Dosing in Phase 1 Clinical Trial of APX001, a Novel Antifungal Product Candidate for Treatment of Life-Threatening Infections 96
Aug 24, 2016: SCYNEXIS Receives Orphan Drug Designation for SCY-078 for the Treatment of Invasive Aspergillus Infections 97
Jun 16, 2016: Antifungal work lands SBU professor $6 million from NIH 97
Jun 14, 2016: Amplyx Pharmaceuticals Announces Qualified Infectious Disease Product Designation for APX001 in Three Life-threatening Fungal Infections 99
May 24, 2016: Amplyx Pharmaceuticals Appoints Paul C. Grint, M.D., to Board of Directors 100
Mar 30, 2016: FDA Grants Vical Fast Track Designation for VL-2397 for the Treatment of Invasive Aspergillosis 100
Mar 07, 2016: Vical Initiates Phase 1 Trial of Novel Antifungal Compound VL-2397 101
Jan 28, 2016: SCYNEXIS Receives FDA Fast Track and QIDP Designations for Intravenous Formulation of SCY-078 for the Treatment of Patients with Invasive Fungal Infections 101
Jan 06, 2016: FDA Grants Vical Orphan Drug Designation for VL-2397 for the Treatment of Invasive Aspergillosis 102
Dec 17, 2015: Matinas BioPharma's Lead Antifungal Product Candidate MAT2203 Granted QIDP and Fast Track Designations for Treatment of Aspergillus by U.S. FDA 103
Nov 30, 2015: F2G to Participate in the Adaptive Pathways Pilot Programme 103
Sep 21, 2015: SCYNEXIS Presents Data Supporting the Potential Clinical Utility of Antifungal Drug Candidate at ICAAC/ICC 2015 104
Sep 15, 2015: Vical to Present Preclinical Data at ICAAC 2015 Meeting for Its Novel Antifungal Drug Candidate VL-2397 105
Aug 19, 2015: FDA Grants Qualified Infectious Disease Product Designation to VL-2397, Vical's Antifungal Product Candidate 105
Appendix 107
Methodology 107
Coverage 107
Secondary Research 107
Primary Research 107
Expert Panel Validation 107
Contact Us 107
Disclaimer 108

List of Tables

Number of Products under Development for Aspergillosis, H2 2016 11
Number of Products under Development for Aspergillosis - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Late Stage Development, H2 2016 16
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Development, H2 2016 18
Comparative Analysis by Unknown Stage Development, H2 2016 19
Products under Development by Companies, H2 2016 20
Products under Investigation by Universities/Institutes, H2 2016 21
Aspergillosis - Pipeline by Amplyx Pharmaceuticals, Inc., H2 2016 22
Aspergillosis - Pipeline by Astellas Pharma Inc., H2 2016 23
Aspergillosis - Pipeline by Biomar Microbial Technologies, H2 2016 24
Aspergillosis - Pipeline by Biosergen AS, H2 2016 25
Aspergillosis - Pipeline by Cidara Therapeutics, Inc., H2 2016 26
Aspergillosis - Pipeline by F2G Ltd, H2 2016 27
Aspergillosis - Pipeline by Hsiri Therapeutics LLC, H2 2016 28
Aspergillosis - Pipeline by iCo Therapeutics Inc., H2 2016 29
Aspergillosis - Pipeline by Matinas BioPharma Holdings, Inc. , H2 2016 30
Aspergillosis - Pipeline by Merck & Co., Inc., H2 2016 31
Aspergillosis - Pipeline by Nanomerics Ltd, H2 2016 32
Aspergillosis - Pipeline by Novabiotics Limited, H2 2016 33
spergillosis - Pipeline by Pulmatrix, Inc., H2 2016 34
Aspergillosis - Pipeline by Pulmocide Ltd, H2 2016 35
Aspergillosis - Pipeline by Scynexis, Inc., H2 2016 36
Aspergillosis - Pipeline by Sealife PHARMA GMBH, H2 2016 37
Aspergillosis - Pipeline by Sigma-Tau S.p.A., H2 2016 38
Aspergillosis - Pipeline by TGV-Laboratories, H2 2016 39
Aspergillosis - Pipeline by Vical Incorporated, H2 2016 40
Assessment by Monotherapy Products, H2 2016 41
Number of Products by Stage and Target, H2 2016 43
Number of Products by Stage and Mechanism of Action, H2 2016 45
Number of Products by Stage and Route of Administration, H2 2016 47
Number of Products by Stage and Molecule Type, H2 2016 49
Aspergillosis - Dormant Projects, H2 2016 94
Aspergillosis - Discontinued Products, H2 2016 95